anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
Shaochuan Liu(Tianjin Medical University Cancer Institute and Hospital), Kai Li(Guangdong Academy of Medical Sciences)
Cited by 185
Related Papers
<p>Overexpression of RNF126 Promotes the Development of Colorectal Cancer via Enhancing p53 Ubiquitination and Degradation</p>
|OncoTargets and Therapy|2020|16
Immune‐independent acquired resistance to <scp>PD‐L1</scp> antibody initiated by <scp>PD‐L1</scp> upregulation via <scp>PI3K</scp>/<scp>AKT</scp> signaling can be reversed by anlotinib
|Cancer Medicine|2023|13